New therapeutic strategies for the treatment and prevention of head and neck cancer

Bibliography

• VOKES EE, WEICHSELBAUM RR, LIPPMAN SM, HONG WK: Head and neck cancer. N. Engl. J. Med. (1993) 328:184–194.
   PubMed Web of Science ®Google Scholar
• BORING CC, SQUIRE TS, TONG T, MONTGOMERY S: Cancer statistics. CA. Cancer J. Clin. (1994) 44:7–26.
   PubMed Web of Science ®Google Scholar
• BOURHIS J, PIGNON JP, DESIGNE L et al.: Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): (1) Locoregional treatment vs. same treatment + chemotherapy. Proc. Am. Soc. Clin. Oncol (1998) 17:386a.
   Google Scholar
• STUPP R, CHUNG TDK, COLLINS SL, DOUGHERTY MJ, WEICHSELBAUM RR, VOKES EE: Head and neck. In: Clinical Oncology (Second Edition). Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE, (Eds.), Churchill Livingstone, Philadelphia, USA (2000).
   Google Scholar
• KISH JA, WEAVER A, JACOBS J et al.: Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck. Cancer (1984) 53: 1819-1824.
   Google Scholar
• JACOBS C, LYMAN G, VELEZ GARCIA E et al.: A Phase IIIrandomized study comparing cisplatin and fluorou-racil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin. Oncol. (1992) 10:257–263.
   Google Scholar
• FORASTIERE AA, METCH B, SCHULLER DE et al.: Random-ized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J. Clin. Oncol (1992) 10:1245–1251.
   PubMed Web of Science ®Google Scholar
• BROWMAN GP, CRONIN L: Standard chemotherapy in squamous cell head and neck cancer: What we have learned from randomized trials. Semin. Onco/. (1994) 21:311–319.
   PubMed Web of Science ®Google Scholar
• EISENBERGER, M, VAN ECHO D, AISNER J: Carboplatin: The experience in head and neck cancer. Semin. Oncol (1989) 16:34–41.
   PubMed Web of Science ®Google Scholar
• MILAS L, MILROSS CG, MASON KA: Cytotoxic treatments and tumour oxygenation. Canced Sci. Am. (1996) 2:59.
   PubMedGoogle Scholar
• MILAS L, HUNTER NR, MASON KA et al.: Enhancement oftumour radioresponse of a murine mammary carcinoma by paclitaxel. Cancer Res. (1994) 54:3506–3510.
   PubMed Web of Science ®Google Scholar
• THE DEPARTMENT OF VETERANS AFFAIRS LARYNGEAL CANCER STUDY GROUP: Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl. J Med. (1991) 324:1685–1690.
   PubMed Web of Science ®Google Scholar
• WOLFE GT, HONG WK, FISHER SG: Neo adjuvant chemotherapy for organ preservation: Current status. In: 4th International Conference on Head and Neck Cancer. Shah JP, Johnson JT (Eds.), Society of Head and Neck Surgeons and American Society of Head and Neck Surgery, Toronto, Canada (1996) :89.
   Google Scholar
• Adjuvant chemotherapy for advanced head and neck squamous carcinoma. Final report of the Head and Neck Contracts Program. Cancer (1987) 60:301–311.
   PubMed Web of Science ®Google Scholar
• SCHULLER DE, METCH B, STEIN DW et al.: Preoperative chemotherapy in advanced resectable head and neck cancer: Final report of the Southwest Oncology Group. Laryngoscope (1998) 98:1205–1211.
   Google Scholar
• LARAMORE GE, SCOTT CB, AL-SARRAF M et al.: Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: Report on Intergroup study 0034. Int. J. RadiaL Oncol. Biol. Phys. (1992) 23:705–713.
   Web of Science ®Google Scholar
• LEFEBVRE JL, CHEVALIER D, LUBOINSKI B et al: larynx preservation in pyriform sinus cancer: Preliminary results of a European Organization for Research and Treatment of Cancer Phase III trial: EORTC Head and Neck Cancer Co-operative Group. J. Nail Cancer Inst. (1996) 88:890–899.
   PubMed Web of Science ®Google Scholar
• PACCAGNELLA A, ORLANDO A, MARCHIORI C et al.: Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: A study by the Gruppo di Studio sui Tumouri della Testa e del Collo. J Natl. Cancer Inst. (1994) 86:265–272.
   PubMed Web of Science ®Google Scholar
• LO TC, WILEY AL, JR., ANSFIELD FJ et al: Combined radiation therapy and 5-fluorouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx: A randomized study. Am. J. Roentgenol. (1976) 126:229–235.
   Google Scholar
• SHANTA V, KRISHNAMURTHI S: Combined bleomycin and radiotherapy in oral cancer. Clin. Radio]. (1980) 31:617–620.
   PubMed Web of Science ®Google Scholar
• FU KK, PHILLIPS TL, SILVERBERG IJ et al.: Combined radiotherapy and chemotherapy with bleomycin and methotrex ate for advanced inoperable head and neck cancer: Update of a Northern California Oncology Group randomized trial. J. Clin. Oncol. (1987) 5:1418.
   Google Scholar
• GUPTA NK, POINTON RC, WILKINSON PM: A random-ized clinical trial to contrast radiotherapy with radiotherapy and methotrexate given synchronously in head and neck cancer. Clin. Radio]. (1987) 38:575–581.
   PubMed Web of Science ®Google Scholar
• WEISSBERG JB, SON YH, PAPAC RJ et al: Randomized clinical trial of mitomycin C as an adjunct to radiotherapy in head and neck cancer. Int. J RadiaL Oncol. Biol. Phys. (1989) 17:3–9.
   Web of Science ®Google Scholar
• SANCHIZ F, MILLA A, TORNER J et al: Single fraction per day versus two fractions per day versus radiochemo-therapy in the treatment of head and neck cancer. Int. J. RadiaL Oncol. Biol. Phys. 19:1347-1350.
   Google Scholar
• BACHAUD JM, COHEN-JONATHAN E, ALZIEN C et al: Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: Final report of a randomized trial. Int. J RadiaL Oncol. Biol. Phys. (1996) 36:999–1004.
   Web of Science ®Google Scholar
• HAFFTY BG, SON YH, SASAKI CT et al: Mitomycin C as an adjunct to postoperative radiation therapy in squamous cell carcinoma of the head and neck: Results from two randomized clinical trials. Int. J RadiaL Oncol. Biol. Phys. (1993) 27:241–250.
   Web of Science ®Google Scholar
• SMID L, LESNICAR H, ZAKOTNIK B et al: Radiotherapy,combined with simultaneous chemotherapy with mitomycin C and bleomycin for inoperable head and neck cancer - preliminary report. Int. j RadiaL Oncol Biol. Phys. (1995) 32:769–775.
   Web of Science ®Google Scholar
• ADELSTEIN DJ, SAXTON JP, LAVERTU P et al: Concurrentradiation and chemotherapy (CT) versus radiotherapy (RI) alone in resectable stage III and IV squamous cell head and neck cancer (SCHNC):APhase III randomized trial. Proc. Am. Soc. Clin. Oncol. (1996) 15:26.
   Google Scholar
• GABRIELE P, TESSA M, RAGONA R et al: An interimanalysis of Phase III study on radiotherapy (RI) versus RTplus carboplatin (CBDCA) in inoperable stage III-W head and neck (H&N) carcinoma. In: 4th International Conference on Head and Neck Cancer. The Society of Head and Neck Surgeons and American Society of Head and Neck Surgery, Toronto, Canada (1996):116.
   Google Scholar
• WUSTROW TPU, WENDT TG, GRABENBAUER G et al.:Randomized Phase III study for simultaneous radiopolychemotherapy in head and neck cancer. In: 4th International Conference on Head and Neck Cancer. The Society of Head and Neck Surgeons and American Society of Head and Neck Surgery, Toronto, Canada (1996):117.
   Google Scholar
• BRIZEL D, ALBERS M, FISHERS et al: A Phase III trial ofhyperfractionated irradiation ± concurrent chemotherapy for locally advanced carcinoma of the head and neck: Superiority of combined modality treatment. 4th International Conference on Head and Neck Cancer. The Society of Head and Neck Surgeons and American Society of Head and Neck Surgery, Toronto, Canada (1996):117.
   Google Scholar
• AL-SARRAF M, LEBLANC M, SHANKER GIRI PG et al.: Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099. J. Clin. Oncol (1998) 16:1310–1317.
   Google Scholar
• RENTSCHLER RE, WILBUR DW, PETTI GH et al.: Adjuvant methotrex ate escalated to toxicity for resectable stage III and IV squamous head and neck carcinomas - a prospective, randomized study. j Clin. Oncol. (1987) 5:278–285.
   PubMed Web of Science ®Google Scholar
• TAYLOR SG, APPLEBAUM E, SHOWEL JL et al: A random-ized trial of adjuvant chemotherapy in head and neck cancer. J Clin. Oncol. (1985) 3:672–679.
   PubMed Web of Science ®Google Scholar
• KUN LE, TOOHILL RJ, HOLOYE PY et al.: A randomizedstudy of adjuvant chemotherapy for cancer of the upper aerodigestive tract. Int. J. Radiat Oncol. Biol. Phys. (1986) 12:173–178.
   PubMed Web of Science ®Google Scholar
• SZPIRGLAS H, CHASTANG C, BERTRAND JC: Adjuvant treatment of tongue and floor of the mouth cancers. Recent Results Cancer Res. (1978) 68:309–317.
   PubMedGoogle Scholar
• ERVIN TJ, CLARK JR, WEICHSELBAUM RR et al.: Ananalysis of induction and adjuvant chemotherapy in the multidisciplinary treatment of squamous-cell carcinoma of the head and neck. J Clin. Oncol (1987) 5:10–20.
   PubMed Web of Science ®Google Scholar
• ROSSI A, MOLINARI R, BORACCHI P et al: Adjuvant chemotherapy with vincristine, cyclophosphamide and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: Results of a 4-year multicenter randomized study. j Clin. Oncol. (1988) 6:1401–1410.
   PubMed Web of Science ®Google Scholar
• BOURHIS J, PIGNON JP, DESIGNE L et al: Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): (1) Loco-regional treatment vs. same treatment + chemotherapy. Proc. Am. Soc. Clin. Oncol. (1998) 17:386a.
   Google Scholar
• BRENNER DJ: Toward optimal external-beam fractiona-tion for prostate cancer. Int. J RadiaL Oncol Biol. Phys. (2000) 48(2):315–316.
   Web of Science ®Google Scholar
• MENDENHALL WM: Altered fractionation for squamous cell carcinoma of the head and neck. 5th International Conference on Head and Neck Cancer (July 29 - August 2, 2000)63.
   Google Scholar
• PARSON JT, MENDENHALL WM, STRINGER SP et al: Squamous cell carcinoma of the oropharynx: comparative results of primary radiation therapy with or without dissection versus primary resection with or without adjuvant radiation therapy: Analysis of North American series. Proceedings 5th International Conference on Head and Neck Cancer (July 29 - August 2, 2000):71. Abstract 19.
   Google Scholar
• FU KK, PAJAK TF, TROTTI A et al.: A Radiation Therapy Oncology Group (RTOG) Phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int. J RadiaL Oncol Biol Phys. (2000) 48(0:1–2.
   Google Scholar
• EMAMI B, SPECTOR JG: Hypopharynx (Chapter 41). In: Principles and Practice of Radiation Oncology, (3rd Edition). Perez CA, Brady LW (Eds.), Lippincott-Raven Publisher, Philadelphia, USA (1997).
   Google Scholar
• FU KK: Combined radiotherapy and chemotherapy for nasopharyngeal carcinoma. Semin. RadiaL Oncol. (1988) 8(4):247–253.
   Google Scholar
• PEREZ CA, DEVINENI VR, MARCIAL-VEGA V, MARKS JE, SIMPSON JR, KUCIK N: Carcinoma of the nasopharynx: Factors affecting prognosis. Int. j RadiaL Oncol. Phys. (2000) 23(2)271–280.
   Google Scholar
• HARARI PM: Why has induction chemotherapy for advanced head and neck cancer become a United States community standard of practice? j Clin. Oncol. (1997) 15:2050–2055.
   Google Scholar
• PIGNON JP, BOURHIS J, DOMENGE C, DESIGNE L, ONBEHALF OF THE MACH-NC COLLABORATIVE GROUP: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analysis of updated individual data. Lancet (2000) 355:949–955.
   PubMed Web of Science ®Google Scholar
• WOLF GT, HONG WK, DEPARTMENT OF VETERANS AFFAIRS LARYNGEAL CANCER STUDY GROUP: Induction chemotherapy as part of a new treatment strategy to preserve the larynx in advanced laryngeal cancer. In: Head And Neck Cancer, (Volume III). Johnson JT, Didolkar MS (Eds.), Elsevier, Amsterdam, Netherlands (1993):27–35.
   Google Scholar
• RICHARD JM, SANCHO-GARNERI H, PESSEY JJ et al.: Randomized trial of induction chemotherapy in larynx carcinoma. Oral Oncol. (1998) 34:224–228.
   PubMed Web of Science ®Google Scholar
• LEFEBVRE JL, CHEVALIER D, LUBOINSKI B, KIRKPATRICK A, COLLETTE L, SAHMOUD T: larynx preservation in pyriform sinus cancer: Preliminary results of a European organisation for research and treatment of cancer Phase III study. J. Natl. Cancer Inst. (1996) 13:890.
   Google Scholar
• EMAMI B, GRAHAM MV, MICHALSKI JM, PEREZ CA: Three-dimensional conformal radiation therapy: clinical aspects, (Chapter 13). In: Principles and Practice of Radiation Oncology, (3rd Edition). Perez CA, Brady LW (Eds.), Lippincott-Raven Publisher, Philadelphia, USA (1997).
   Google Scholar
• EMAMI B, MIRKOVIC N, CLARK J, MOHIDEEN N, PETRUZZELLI G, LEMAN C: Modern management of advanced squamous cell cancer of nasalpharynx: Preliminary results. Final program and abstract book. 5th International Conference on Head and Neck Cancer. PA 110, USA (July 29 - August 2, 2000212.
   Google Scholar
• MIRKOVIC N, EMAMI B, IZADIFAR N et al.: Three-dimensional conformal radiation therapy (3DCRT) is superior to two-dimensional (2D) in treatment of tumours of paranasal sinuses. Final Program and Abstract Book. 5th International Conference on Head and Neck Cancer. PA224, USA (July 29 - August 2, 2000240.
   Google Scholar
• COLLINS SJ, BASTIAN RW, MARKS J, EMAMI B: Favorable results of organ-preservation surgery plus radiotherapy for poor-prognosis head and neck cancer: An alternative to chemoradiation. Final Program and Abstract Book, 5th International Conference on Head and Neck Cancer. PA370, USA (July 29 - August 2, 2000):277.
   Google Scholar
• EISBRUCH A, SHIP JA, MARTEL MK et al.: Parotid gland sparing in patients undergoing bilateral head and neck irradiation: Techniques and early results. Int. J RadiaL Oncol. Biol. Phys. (1996) 36(2).
   Google Scholar
• MARTEL MK, SANDLER HM, CORNBLATH WY et al.: Dose-volume complication analysis for visual pathway structures of patients with advanced paranasal sinus tumours. Int. J. RadiaL Oncol. Biol. Phys. (1997) 38(2).
   Google Scholar
• EMAMI B, MIRKOVIC N, CLARK J, MOHIDEEN N, PETRUZZELLI G, LEMAN C: Modern management of advanced squamous cell cancer of nasalpharnx: Preliminary results. Final Program and Abstract Book 5th International Conference on Head and Neck Cancer. PA110, USA (July 29 - August 2, 2000212.
   Google Scholar
• WOLDEN SL, ZELEFSKY MJ, PFISTER DG et al.: Improving radiotherapy for nasopharyngeal carcinoma: A 3D boost is not enough. Final Program and Abstract Book 5th International Conference on Head and Neck Cancer. PA110, USA (July 29 - August 2, 200071. Abstract 019.
   Google Scholar
• MIRKOVIC N, EMAMI B, IZADIFAR N et al.: Three-dimensional conformal radiation therapy (3D CRT) is superior to two-dimensional (2D) in treatment of tumours of paranasal sinuses. Final Program and Abstract Book 5th International Conference on Head and Neck Cancer. PA224, USA (July 29 - August 2, 2000)240.
   Google Scholar
• DAY GL, BLOT WJ: Second primary tumours in patientswith oral cancer. Cancer (1992) 70:14–19.
   PubMed Web of Science ®Google Scholar
• SLAUGHTER DP, SOUTHWICK HW, SMEJKAL W: 'Fieldcancerization' in oral stratified squamous epithelium. Cancer (1953) 6:963–968.
   PubMed Web of Science ®Google Scholar
• CHUNG KY, MUKHOPADYAY T, KIM J et al.: Discordantp53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract. Cancer Res. (1993) 53:1676–1683.
   PubMed Web of Science ®Google Scholar
• NEES M, HOMANN N, DISCHER H et al.: Expression ofmutated p53 occurs in tumour-distant epithelia of head and neck cancer patients: a possible molecular basis for the development of multiple primary tumours. Cancer Res. (1993) 53:4189–4196.
   PubMed Web of Science ®Google Scholar
• ZARIWALA M, SCHMID S, PFLATZ M, OHGAKI H, KLEIHUES P, SCHAFER R: p53 gene expression in oropharyngeal carcinomas of solitary and multiple primary tumours and lymph-node metastases. Int. J. Cancer (1994) 56:807–811.
   PubMed Web of Science ®Google Scholar
• KANJILAL S, STROM SS, CLAYMAN GL et al.: p53 mutations in non-melanoma skin cancer of the head and neck: molecular evidence for field cancerization. Cancer Res. (1995) 55:3604–3609.
   PubMed Web of Science ®Google Scholar
• LIPPMAN SM, HONG WK: Second malignant tumours in head and neck squamous cell carcinoma: the overshadowing threat for patients with early-stage disease. Intl RadiaL Oncol. Biol. Phys. (1989)17:691–694.
   PubMed Web of Science ®Google Scholar
• SPORN MB: Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res. (1976) 3 6 :2699–2702.
   Google Scholar
• LIPPMAN SC, BENNER SE, HONG WK: Cancer chemopre-vention. j Clin. Oncol. (1994) 12:851–873.
   PubMed Web of Science ®Google Scholar
• KELLOFF GJ, BOONE CW, STEELE VE, CROWELL JA, LUBET R, SIGMAN CC: Progress in cancer chemopre-vention: perspectives on agent selection and short-term clinical intervention trials. Cancer Res. (1994) 54:2015–2024.
   Google Scholar
• LIPPMAN SC, BENNER SE, HONG WK: Chemopreven-tion: Strategies for the control of cancer. Cancer (1993) 72:984–990.
   PubMed Web of Science ®Google Scholar
• FELDMAN EB: Dietary intervention and chemopreven-tion. Preventive Medicine (1993) 22:661–666.
   PubMed Web of Science ®Google Scholar
• SHKLAR G, SCHWARTZ J, GRAU D, TRICKLER DP, WALLACE DK: Inhibition of hamster buccal pouch carcinogenesis by 13-cis-retinoic acid. Oral Surg. (1980) 50:45–53.
   PubMedGoogle Scholar
• SHKLAR G, FLYNN E, SZABO G, MAREFAT P: Retinoid inhibition of experimental lingual carcinogenesis: ultrastructural observations. J. Natl. Cancer Inst. (1980) 65:1307–1316.
   PubMed Web of Science ®Google Scholar
• SHKLAR G, MAREFAT P, KORNHAUSER A, TRICKLER DP,WALLACE DK: Retinoid inhibition of lingual carcino-genesis. Oral Surg. (1980) 49:325–332.
   PubMedGoogle Scholar
• BURGE-BOTTENBLEY A, SHKLAR G: Retardation ofexperimental oral cancer development by retinyl acetate. Nutr. Cancer (1983) 5:121–129.
   PubMedGoogle Scholar
• HONG WK, ENDICOTT J, ITRI LM et al.: 13-cis-retinoicacid in the treatment of oral leukoplakia. N. Engl. J. Med. (1986) 315:1501–1505.
   PubMed Web of Science ®Google Scholar
• HONG KW, LIPPMAN SM, ITRI LM et al.: Prevention ofsecond primary tumours with isotretinoin in squamous cell carcinoma of the head and neck. N Engl. J. Med. (1990) 323:795–801.
   PubMed Web of Science ®Google Scholar
• LIPPMAN SC, BENNER SE, HONG WK: Chemopreven-tion: Strategies for the control of cancer. Cancer (1993) 72:984–990.
   PubMed Web of Science ®Google Scholar
• AMOS B, LOTAN R: Retinoid-sensitive cells and cell lines. Methods Enzymol. (1990) 190:217–225.
   PubMed Web of Science ®Google Scholar
• ZOU CP, CLIFFORD J, XU XC et al.: Modulation by retinoic acid of squamous differentiation, cellular RA-binding proteins and nuclear RA receptors in human head and neck squamous cell carcinoma cell lines. Cancer Res. (1994) 54:5479–5487.
   PubMed Web of Science ®Google Scholar
• LOTAN R, LOTAN D, SACKS PG: Inhibition of tumourcell growth by retinoids. Methods Enzymol. (1990) 190:100–110.
   PubMed Web of Science ®Google Scholar
• LOTAN R: Cellular biology of the retinoids. In: Retinoids in Oncology Dego L, Parkinson DR (Eds.), Spriner, Berlin, Germany (1995):27–42.
   Google Scholar
• LOTAN R: Retinoids and apoptosis: implications for cancer chemoprevention and therapy. J. Nati Cancer Inst. (1995) 87:1655–1657.
   PubMed Web of Science ®Google Scholar
• LOTAN R: Retinoids in cancer chemoprevention. FASEB J. (1996) 10:1031–1039.
   PubMed Web of Science ®Google Scholar
• INGBER D, FOLKMAN J: Inhibition of angiogenesis through modulation of collagen metabolism. Lab. Invest. (1989) 59:44–51.
   Web of Science ®Google Scholar
• OIKAWA T, NAKAMURA 0, SHUDO K, HIRAGUN A, IWAGUCHI T: A highly potent anti-angiogenic activity of retinoids. Cancer Lett. (1989) 48:157–162.
   PubMed Web of Science ®Google Scholar
• ARENSMAN RM, STOLAR CH: Vitamin A effect on tumourangiogenesis. I Pediatr. Surg. (1979) 14:809–813.
   PubMed Web of Science ®Google Scholar
• RUDNICKA L, MARCZAK M, SZMURLO A et al.: Acitretindecreases tumour cell-induced angiogenesis. Skin Pharmacol. (1991) 4:150–153.
   PubMedGoogle Scholar
• MAJEWSKI S, SZMURLO A, MARCZAK M, JABLONSKA S,BOLLAG W: Inhibition of tumour cell-induced angiogenesis by retinoids, 1-25-dihydroxyvitamin D3 and their combination. Cancer Lett. (1993) 75:35–39.
   PubMed Web of Science ®Google Scholar
• MAJKEWSKI S, SZMURLO A, MARCZAK M, JABLONSKA S,BOLLAG W: Synergistic effect of retinoids and interferon-a on tumour-induced angiogenesis: anti-angiogenic effect on hpv-harboring tumour-cell lines. Int. J. Cancer (1994) 57:81–85.
   PubMed Web of Science ®Google Scholar
• MAJEWSKI S, MARCZAK M, SZMURLO A, JABLONSKA S, BOLLAG W: Retinoids, interferon-a, 1,25- dihydroxyvi-tamin D3 and their combination inhibit angiogenesis induced by non-hpv-harboring tumour cell lines. RAR a mediates the anti-angiogenic effects of retinoids. Cancer Lett. (1995) 89:117–124.
   Google Scholar
• LINGEN MW, POLVERINI PJ, BOUCK NP: Retinoic acid induces cells cultured from oral squamous cell carcinomas to become anti-angiogenic. Am. J Pathol. (1996) 149:247–258.
   PubMed Web of Science ®Google Scholar
• GRANDIS JR, ZENG Q, TVVEARDY DJ: Retinoic acid normalizes the increased gene transcription rate of TGF-a and EGFR in head and neck cancer cell lines. Nature Med. (1996) 2:237–240.
   PubMed Web of Science ®Google Scholar
• LIAUDET-COOPMAN EDE, BERCHEM GJ, WELLSTEIN A: In vivo inhibition of angiogenesis and induction of apoptosis by retinoic acid in squamous cell carcinoma. Clin. Cancer Res. (1997) 3:179–184.
   PubMed Web of Science ®Google Scholar
• LINGEN MW, POLVERINI PJ, BOUCK NP: Inhibition of squamous cell carcinoma angiogenesis by direct interaction of retinoic acid with endothelial cells. Lab. Invest. (1996) 74:476–483.
   PubMed Web of Science ®Google Scholar
• LIPPMAN SM, GLISSON BS, KAVANAGH JJ et al.: Retinoic acid and interferon combination studies in human cancer. Eur. J. Cancer (1993) 29A:9–13.
   PubMed Web of Science ®Google Scholar
• MOORE DM, KALVAKOLANU DV, LIPPMAN SM et al: Retinoic acid and interferon in human cancer: mechanistic and clinical studies. Semin. Hematol. (1994) 31:31–37.
   PubMed Web of Science ®Google Scholar
• BROUTY-BOYE D, ZETTER BR: Inhibition of cellmotility by interferon. Science (1980) 208:516–518.
   PubMed Web of Science ®Google Scholar
• SIDKY Y, BORDEN E: Inhibition of angiogenesis by interferons: Effects on tumour and lymphocyte-induced vascular responses. Cancer Res. (1987) 47:5155–5161.
   PubMed Web of Science ®Google Scholar
• FRIESEL R, KOMORIYA A, MACIAG T: Inhibition of endothelial cell proliferation by 7-interferon. J Cell Biol. (1987) 104:689–696.
   PubMed Web of Science ®Google Scholar
• MAHESHWARI RK, SRIKANTAN V, BHARTIYA D, KLEINMAN HK, GRANT DS: Differential effects of interferon '(and a on in vitromodel of angiogenesis. Cell Physiol. (1990) 146:164–169.
   Google Scholar
• RUSZCAK Z, DETMAR M, IMCKE E, ORFANOS CE: Effects of rIFN a, 13 and '(on the morphology, proliferation and cell surface antigen expression of human dermal microvascular endothelial cell in vitro. J. Invest. Dermatol. (1990) 95 :693–699.
   PubMed Web of Science ®Google Scholar
• SAIKI I, SATO K, Y00 YC et al.: Inhibition of tumour-induced angiogenesis by the administration of recombinant interferon-7 followed by a synthetic lipid-A subunit analogue. Int. J. Cancer (1992) 51:641–645.
   Google Scholar
• JONES GJ, ITRI L: Safety and tolerance of recombinant interferon a-2a in cancer patients. Cancer (1996) 57: 1709-1715.
   Google Scholar
• LINGEN MW, POLVERINI PJ, BOUCK NP: Retinoic acid and interferon-a act synergistically to inhibit oral squamous cell carcinoma induced angiogenesis. Cancer Res. (1998) 58:5551–5558.
   PubMed Web of Science ®Google Scholar
• SINGH RK, GUTMAN M, BUCANA CD, SANCHEZ R, LLANSA N, FIDLER IJ: Interferons a and 13 downregulate the expression of basic fibroblast growth factor in human carcinomas. Proc. Natl. Acad. Sci. USA (1995) 92:4562–4566.
   PubMed Web of Science ®Google Scholar
• OLIVEIRA IC, SCIAVOLINO PJ, LEE TH, VILCEK J: Downreg-ulation of interleukin-8 gene expression in human fibroblasts: unique mechanism of transcrip-tional inhibition by interferon. Proc. Natl. Acad. Sci. USA (1992) 89:9049–9053.
   PubMed Web of Science ®Google Scholar
• OLIVEIRA IC, MUKAIDA M, MATUSHIMA K, VILCEK J: Transcriptional inhibition of the IL-8 gene by interferon is mediated by the NF-KB site. Mot. Cell Biol. (1994) 14:5300–5308.
   Web of Science ®Google Scholar
• STREITER RM, KUNKEL SL, ARENBERG DA, BURDICK MD, POLVERINI PJ: Interferon '(inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis. Biochem. Biophys. Res. Commun. (1995) 210:51–57.
   PubMed Web of Science ®Google Scholar
• SGADARI C, ANGIOLILLO AL, TOSATO G: Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood (1996) 87:3877–3882.
   PubMed Web of Science ®Google Scholar
• CLAYMAN GL: The current status of gene therapy. Semin. Oncol (2000) 27:39–43.
   PubMed Web of Science ®Google Scholar
• GANLY I, SOUTAR DS, KAYE SB: Current role of gene therapy in head and neck cancer. Eur. j Surg. Oncol (2000) 26:338–343.
   PubMedGoogle Scholar
• MIZUNO H, YANOMA S, NISHIMURA G eta].: Therapeutic efficiency of IL-2 gene transduced tumour vaccine for head and neck carcinoma. Cancer Lett. (2000) 152:175-185. GLEICH LL: Gene therapy for head and neck cancer. Laryngoscope (2000) 11 0 :708-726 . MYERS JN: The use of biological therapy in cancer of the head and neck. Curr. Prob. Cancer (1999) 23:106-134. LANG S, WHITESIDE TL, LEBEAU A, ZEIDLER R, MACK B, WOLLENBERG B: Impairment of T-cell activation in head and neck cancer in situ and in vitro: strategies for an immune restoration. Arch. Otolmyngol. Head Neck Surg. (1999) 125:82–88.
   Google Scholar
• RESSER JR, CARBONE DP: Irnmunotherapy of head and neck cancer. Curr. Opin. Oncol (1998) 10(3):226–232.
   PubMedGoogle Scholar
• KHURI FR, NEMUNAITIS J, GANLY I et al.: A controlled trial of intratumoural ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nature Med. (2000) 6:879–885.
   PubMed Web of Science ®Google Scholar
• CLAYMAN GL, FRANK DK, BRUSO PA, GOEPFERT H: Adenovirus-mediated wild type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin. Cancer Res. (1999) 5:1715–1722.
   PubMed Web of Science ®Google Scholar
• MAUCERI H, HANNA NN, WAYNE JD, HALLAHAN DE, HELLMAN S, WEICHSELBAUM RR: Tumour necrosis factor a (TNF-a) gene therapy targeted by ionizing radiation selectively damages tumour vasculature. Cancer Res. (1996) 56:4311–4314.
   PubMed Web of Science ®Google Scholar
• RUDIN CM, RECANT W, BENNETT P, SULTZEN L, KIRN DH, VOKES EE: Preliminary report: adenovirus onyx-015 administered by mouthwash as a chemopre-ventative agent and for the treatment of oral dysplastic lesions. Proc. Am. Soc. Clin. Oncol. (1999) 18:445A.
   Google Scholar